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Wavelet transform of polarized fluorescence spectroscopic data of human breast tissues is found
to reliably differentiate normal and malignant tissue types and isolate characteristic biochemical
signatures of cancerous tissues, which can possibly be used for diagnostic purpose. A number of
parameters capturing spectral variations and subtle changes in the diseased tissues in the visible
wavelength regime are clearly identifiable in the wavelet domain. These investigations, corroborated
with tissue phantoms, indicate that the observed differences between malignant tumor and normal
samples are primarily ascribable to the changes in concentration of porphyrin and density of cellular
organelles present in tumors.
PACS numbers: 87.64.-t, 87.64Ni, 86.66Xa
Breast cancer has emerged as the most common disease
amongst women [1]. Although the risk factor for Asian
women has been estimated to be one-fifth to one-tenth
that of women in North America and Western Europe, it
still is the second most malignant condition [2, 3]. Apart
from genetic predisposition, a number of factors like diet,
exercise, environment, etc., are being recognized to play
major roles in the growth of the disease [4]. Early diag-
nosis is still not possible through conventional diagnostic
techniques. If diagnosed early, breast cancer is also one
of the most treatable forms of cancer. The requirement
of continuous monitoring for breast malignancy of a sig-
nificant percentage of women population has led to an
intense search for safe, reliable and fast diagnostic meth-
ods.
Optical diagnosis techniques are now emerging as vi-
able tools for tumor detection. Of these, fluorescence
techniques are being increasingly employed to investi-
gate both morphological and biochemical changes in dif-
ferent tissue types, for eventual application in the de-
tection of tumors at an early stage [5]. Fluorescence
spectroscopy is well suited for the diagnosis of cancer-
ous tissues because of its sensitivity to minute variations
in the amount and the local environment of the native
fluorophores present in the tissues [6, 7, 8, 9, 10]. Mor-
phological changes prevalent in tumors, such as enlarge-
ment and hyperchromasia of nuclei, overcrowding and
irregular cellular arrangement are known to alter light
propagation and scattering properties in such media and
hence affect the fluorescence spectra [11]. A number of
fluorophores ranging from structural proteins to various
enzymes and coenzymes, some of which participate in
the cellular oxidation-reduction processes, are present in
the human tissue and can be excited by ultraviolet and
visible light [6]. The fluorophores, FAD (Flavin Adenine
Dinucleotide), its derivatives and porphyrins are partic-
ularly useful as fluorescent markers, since they fluoresce
in the higher wavelength visible region, when excited by
lower wavelength visible light, thereby avoiding the po-
tentially harmful ultraviolet radiation.
The fluorescence emission can differ significantly in
normal and cancerous tissues due to the differences in
concentrations of absorbers [12, 13] and scatterers, as
also the scatterer sizes [14]. The absorption in the visi-
ble range occurs primarily due to the presence of blood,
whose amounts vary in various tissue types [15]. The
presence of scatterers leads to randomization of light,
thereby generating a depolarized component in the flu-
orescence spectra. Polarized fluorescence spectroscopy
is useful in isolating the characteristic spectral features
from the diffuse background. The parallel component of
the fluorescence suffers fewer scattering events. In com-
parison, the intensity of the perpendicular component is
not only affected more by scatterers, but is also quite
sensitive to absorption, since the path traversed by the
same in the tissue medium is more. Hence, the difference
of parallel and perpendicular intensities, apart from be-
ing relatively free from the diffusive component [16], can
be quite sensitive to microscopic biochemical changes in-
cluding the effects of absorption in different tissue types.
A number of studies conducted so far have established
certain broad morphological and biochemical changes oc-
curring in tumor tissues, which leave characteristic sig-
natures in the spectral domain [17]. The analyses of
spectral data involve both physical [18, 19, 20, 21] and
statistical [15, 22] modelling of tissue types, as also sta-
tistical methods, e.g., principal component analysis for
extracting distinguishing parameters for diagnostic pur-
poses [15] . The fact that biological tissues are complex
systems, possessing substantial variations among individ-
ual patients, depending upon various factors such as age,
progress of the disease, etc., makes modelling of the same
rather difficult. In using statistical tools, difficulty often
arises in relating the statistically significant quantities to
physically transparent spectral variables. In recent times,
wavelet transform has emerged as a powerful tool for the
2analysis of transient data and is particularly useful in
disentangling characteristic variations at different scales
[23]. This linear transform isolates local features and
leads to a convenient dimensional reduction of the data
in the form of low-pass (average) coefficients, resembling
the data itself. The wavelet or high-pass coefficients, at
various levels, encapsulate the variations at correspond-
ing scales. The higher-level coefficients, particularly the
global parameters associated with them, like power, are
less contaminated by statistical and experimental uncer-
tainties present in the data. An earlier study, of the
perpendicular component of the fluorescence spectra, by
some of the present authors has indicated the usefulness
of wavelet transform in identifying characteristic spectral
features [24].
Here, we present the results of a systematic analysis
of the wavelet transform of the fluorescence spectra from
human breast tissues for malignant and normal tissues.
The difference between parallel and perpendicular com-
ponents of the fluorescence spectra is subjected to this
analysis, since the same is comparatively free of the dif-
fusive component. A number of parameters, capturing
spectral variations and subtle changes in the intensity
profile of the diseased tissues, as compared to their nor-
mal counterparts, are identified in the wavelet domain.
Based on earlier investigations and the present study of
tissue phantoms, the physical origin of these distinguish-
ing parameters can be primarily ascribed to the changes
in the concentration of porphyrins and the density of cel-
lular organelles present in tumors [14, 25].
In total, 28 breast cancer tissue samples were stud-
ied; out of these, 23 samples came with their normal
counterparts. The tissue samples were excited by 488nm
wavelength polarized light and the parallel and perpen-
dicularly polarized fluorescence light were measured from
500 to 700 nm. Differences of parallel and perpendicu-
lar components of fluorescence intensity (I‖ − I⊥) versus
wavelength profiles for all the tissue samples were ana-
lyzed by Haar wavelets [26].
We have identified three independent parameters, de-
rived from the coefficients in the transform domain,
which differentiate cancer and normal tissues quite ac-
curately. The first parameter is the local maxima in
the third quarter of the fourth level low-pass coefficients.
As will be elaborated later, this feature owes its origin
to porphyrin emission [17, 25]. The other two param-
eters are based on wavelet high-pass coefficients, repre-
senting both global and characteristic local variations of
the fluorescence spectra. In the domain of these three
parameters, all the malignant and normal tissues studied
here could be accurately differentiated. The five unpaired
samples were used as checks for the consistency of two of
the chosen parameters, since one of the parameters is a
ratio, which involves both tissue types. Studies on tissue
phantoms, corroborating the above choice of parameters
and the inferences about the aforementioned biochemical
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FIG. 1: Plot of the difference of parallel and perpendicular
components of the fluorescence spectra for tumor and normal
tissues. Inset shows the corresponding fourth level low-pass
coefficients.
changes in the tissues are presented below for compari-
son.
In the fourth level low-pass coefficients, the one orig-
inating from the fluorescence signals around 630 nm of
the original data is found to be considerably higher in
cancer tissues as compared to the corresponding normal
ones. This is possibly due to the presence of more por-
phyrin as well as scattering agents. A particularly noisy
fluorescence data of (I‖ − I⊥) from cancer and normal
human breast tissues does not reveal significant differ-
ences (Fig.1). However, the low-pass wavelet coefficients
of the same data (Fig.1, inset) capture these differences
quite remarkably, highlighting the usefulness of wavelet
analysis.
The local maxima at third quarter of fourth level low-
pass coefficients of cancer samples are more than 0.1
while those of normal tissues are less than 0.1, with a
sensitivity of 100% and specificity of 83% (Fig. 2). It
should be noted here that the values for normal tis-
sues which are more than 0.1 still show lower values
than the corresponding tumors, consistent with all the
other samples. Thus intra-patient diagnosis gives a clear
distinction between cancer and normal tissues. Varia-
tions in inter-patient diagnosis may be due to the fact
that, the growth of tumor depends on genetic (major
genes, modifier genes) and non-genetic factors (birth,
age, weight/diet, exercise, environmental exposures, etc)
[4].
An important observation here is that the 630 nm band
gets emphasized only in the fourth level low-pass coeffi-
cients. This band is masked by other noisy signals at the
third level and is averaged out at the fifth level (Fig. 3).
In cases where the fourth level does not highlight this
band, the previous level does.
FAD and porphyrins are the major fluorophores that
fluoresce in the visible wavelength regime, with peak in-
tensities at 530 and 630 nm respectively. These fluo-
rophores are considered as contrast agents for cancer de-
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FIG. 2: . Local maxima at third quarter of fourth level low-
pass coefficients of cancer and normal breast tissues
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FIG. 3: Low-pass wavelet coefficients of a cancer tissue spec-
tra, (a) third level, (b) fourth level, and (c) fifth level. The
fourth-level coefficients highlight the 630 nm weak emission
peak.
tection [6, 10, 17]. It has been suggested that deficiency
in ferrochelatase, the enzyme required for conversion of
protoporphyrin IX (PpIX) to heme, in tumors results in
accumulation of PpIX in these tissues relative to the nor-
mal ones (10)[10]. Such accumulation changes the rela-
tive concentration of these fluorophores thus altering the
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FIG. 4: (a). Fourth level low-pass coefficients of phantoms
with fixed FAD (20 M) and porphyrin (10 M) concentrations
and varying scatterer concentrations, (i) s =10 mm-1, (ii) s
=20 mm-1, and (iii) s =30 mm-1. Inset shows the values of
the 7th to 10th low-pass wavelet coefficients of the same phan-
toms, highlighting the variations of a local peak. (b) Fourth
level low-pass coefficients of phantoms, with fixed FAD (20 M)
and scatterer (10 M) concentrations and varying porphyrin
concentrations (i) 10 M, and (ii) 20 M.
fluorescence spectra significantly, which in turn changes
the peak heights of the emission bands of the two fluo-
rophores. The scattering centers are known to enhance
the fluorescence intensity [27]. Thus the large size of cell
suspensions, higher density of cells and accumulation of
more porphyrin in tumors all contribute to a small peak
at 630 nm wavelength region.
Studies of tissue models show that the 630 nm band
gets enhanced at the fourth level low-pass coefficients of
phantoms, with an increase in the scatterer concentra-
tions (Fig. 4a) as well as with increase in porphyrin con-
centrations (Fig. 4b). A small peak around 630 nm is
clearly visible at suitable concentrations. Significantly, in
these tissue phantoms too, the third and fifth level low-
passes do not highlight the 630 nm band, as observed in
tissue samples.
The power spectra at different levels are defined as the
sum of the square of high-pass coefficients at those levels.
Normalization of the power spectra is done by dividing
it by the sum of the square of intensities at all the wave-
lengths. In twenty two paired samples, it was found that
the tumors have lower power at the third level as com-
4pared to their normal counterparts with a sensitivity of
96%.
It was also found that, in case of the cancer tissues,
the third wavelet coefficient at the fifth level (originating
from the fluorescence emission at 580 to 596 nm region
in the original spectrum), is less negative than those of
the normal ones. This implies that the normal tissue
fluorescence spectra fall more sharply than those of the
cancer tissues. Out of 28 cancer samples, which includes
23 paired and 5 unpaired tissues, 21 samples have third
coefficients less than -0.31; out of 23 normal tissue sam-
ples, 14 samples have third coefficients more than -0.31.
However, intra-patient diagnosis by high-pass coefficients
shows that the third coefficient, for 17 out of 23 paired
samples of normal tissues, is more than that of cancer-
ous ones. Hence, for this coefficient, the cancer to normal
ratio is less than one, with a sensitivity of 74%.
It may be noted that the above-mentioned three pa-
rameters also distinguish tumors of different grades. It is
found that for grades I and II cancerous tissues the values
of the local low-pass maxima at the third quadrant are
less than 0.2, but more than 0.2 in the grade III cancers,
with a sensitivity of 75%. At third level, the power ratio
is less than 0.3 for grade I and grade II cancers and is
between 0.3 to 0.8 for grade III cancers.
In conclusion, the systematic separation of variations
at different wavelength scales and the broad spectral fea-
tures in the wavelet domain pinpoints several quantifi-
able parameters to distinguish cancer and normal tissues.
These distinguishable features are related with the bio-
chemical and morphological changes, as is also evident
from the phantom study. The fact that these character-
istic signatures are based on higher level wavelet coeffi-
cients make them robust and less susceptible to exper-
imental and statistical uncertainties. The need for the
early identification and constant monitoring of breast
cancer for a large population makes this method emi-
nently suitable since the same can be automated.
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